Grit Biotechnology
Grit Biotechnology
Explore linked clinical trials.19 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases | autoimmune disease, immune system disorder | Recruiting | Early phase 1 | 2026-09-18 | NCT07122076 | |
| GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT06948981 | |
| TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors | Solid Tumors, Adult | Active, not recruiting | Phase 1 | 2026-09-18 | NCT06088472 | |
| GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors | Solid Tumors, Adult | Recruiting | Phase 1 | 2026-09-14 | NCT05430373 | |
| A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Early phase 1 | 2026-09-11 | NCT07676006 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, glomerulonephritis, immune system disorder, kidney disorder, membranous glomerulonephritis, necrotizing vasculitis, nephritis, skin disorder, skin vascular disease, urinary system disorder, vascular disorder, vasculitis | Not yet recruiting | Early phase 1 | 2026-09-11 | NCT07389499 | |
| GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases | Neurological Autoimmune Diseases | Recruiting | Phase 1 | 2026-09-11 | NCT07021209 | |
| Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT06144671 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Early phase 1 | 2026-07-20 | NCT07205315 | |
| A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases | Moderate to Severe Refractory Autoimmune Disease | Recruiting | Early phase 1 | 2026-05-27 | NCT07333118 | |
| Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Not applicable | 2026-04-24 | NCT06190275 | |
| GT719 Injection for Moderate to Severe Refractory Autoimmune Disease | Auto Immune Disease | Recruiting | Early phase 1 | 2026-04-16 | NCT07132112 | |
| Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer | Adult | Recruiting | Phase 2 | 2026-04-15 | NCT06241781 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD) | cGVHD | Recruiting | Early phase 1 | 2026-04-14 | NCT07253259 | |
| IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma | Adult; Advanced Clear Renal Cell Carcinoma | Recruiting | Phase 1 | 2026-04-14 | NCT06819293 | |
| Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer | Adult | Recruiting | Not applicable | 2026-04-14 | NCT06819280 | |
| Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours | Adult | Recruiting | Not applicable | 2026-04-14 | NCT06453057 | |
| Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours | Solid Tumor, Adult | Recruiting | Not applicable | 2026-01-26 | NCT06397963 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Early phase 1 | 2025-12-30 | NCT07131254 |